MCRPC: dual PET/CT imaging helps identify ARSi resistance

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Positron emission tomography (PET) imaging of metastatic castration-resistant prostate cancer (mCRPC) lesions for glycolysis (Gly) using fluoro-2-D-deoxyglucose F 18 ([18F]-FDG), and androgen receptor (AR) using fluorodihydrotestosterone F 18 ([18F]-FDHT), revealed significant het...